Uremic Toxicity of Advanced Glycation End Products in CKD. - Wikidata - wikimedia - TriplyDB

Uremic Toxicity of Advanced Glycation End Products in CKD.

Uremic Toxicity of Advanced Glycation End Products in CKD.

http://www.wikidata.org/entity/Q36514906

about

New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease Dietary interventions to contrast the onset and progression of diabetic nephropathy: A critical survey of new data.Dietary Metabolites and Chronic Kidney Disease.Diet and Diabetic Kidney Disease: Plant Versus Animal Protein.Vitreous advanced glycation endproducts and α-dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls.Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia Challenges and opportunities for stem cell therapy in patients with chronic kidney disease Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes.Inhibition of autophagy increased AGE/ROS-mediated apoptosis in mesangial cells.RAGE and glyoxalase in kidney disease.Endothelial cells: source, barrier, and target of defensive mediators.Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis.Impact of Dietary Fibers on Nutrient Management and Detoxification Organs: Gut, Liver, and Kidneys.Inflammation and premature aging in advanced chronic kidney disease.Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes.Does supplementation with carnosine improve cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes? study protocol for a randomised, double-blind, placebo-controlled trial.Evaluation of the C-domain of heparanase during AGE-induced macrophage inflammatory response Generation and characterization of monoclonal antibody against Advanced Glycation End Products in chronic kidney disease.Redox homeostasis in stomach medium by foods: The Postprandial Oxidative Stress Index (POSI) for balancing nutrition and human health.Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation.Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.AGEs-RAGE overexpression in a patient with smoking-related idiopathic nodular glomerulosclerosis.Skin Autofluorescence Examination as a Diagnostic Tool for Mild Cognitive Impairment in Healthy People.Sevelamer reduces endothelial inflammatory response to advanced glycation end products.Complement Activation in Peritoneal Dialysis-Induced Arteriolopathy.Growth arrest specific 2-like protein 1 expression is upregulated in podocytes through advanced glycation end-products.DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.Diphlorethohydroxycarmalol Attenuates Methylglyoxal-Induced Oxidative Stress and Advanced Glycation End Product Formation in Human Kidney Cells.Glycaemic control in type 2 diabetic patients with chronic kidney disease: the impacts on enzymatic antioxidants and soluble RAGE.Eucommia ulmoides Ameliorates Glucotoxicity by Suppressing Advanced Glycation End-Products in Diabetic Mice Kidney.Association of advanced glycation end products in Dupuytren disease.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).Advanced glycation end products (AGEs) estimated by skin autofluorescence are related with cardiovascular risk in renal transplant Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging Pharmacologic control of oxidative stress and inflammation determines whether diabetic glomerulosclerosis progresses or decreases: A pilot study in sclerosis-prone mice Ameliorates Diabetes-Induced Renal Damage by Suppressing Advanced Glycation End Products in db/db Mice

P2860

Q26739475-9AF9F802-342D-4411-BD49-2D47791A742E Q31157315-D80C9F23-DF66-4F9C-9750-53654D78B397 Q33616732-15D76890-E399-42C2-A86F-E66C9840D5E2 Q33889472-50BCA98B-4AAA-4061-9D35-CBB533CB9961 Q36298479-3A68E332-00B4-4819-B902-71F8F9263D2B Q36357758-B7B0E534-B6DF-4C84-B239-E78A31D342A0 Q36711673-1332EC5C-1439-4FAE-BA82-6F55626D7C64 Q37156126-F9CB7A00-299C-4F43-82D1-CF8492000B68 Q37603335-BF4AA967-733D-40E2-8D54-060F88EF28C1 Q38857649-726DD6CA-D5A0-4E43-826E-7BCD345C2E65 Q38991026-CBABCAF9-86C6-49AA-8E94-3CC98FB88BE0 Q39096507-E56C7CF5-4468-47DF-AA5D-D94CB5085BCB Q39111416-8A2E1171-7FE1-47C9-AC8D-625E60D1DF04 Q39309490-EA448407-735B-4C99-9317-E6DD673A1AEC Q39409210-3089A931-DF60-497B-9FA7-D4BAD67C1193 Q40060825-46B3146B-BC2D-4615-88E1-FE29D298C240 Q41116290-CCFFAFBD-F3E5-420E-9C10-E876A3E8F84A Q41683128-C0E5ED35-1E2B-49C7-AE99-C04188A006F4 Q41777487-69B9F9DF-F520-4153-A047-C8ED3DD42AD2 Q45339625-E7792590-2398-415D-AE6D-4F74ACF54811 Q47216784-6E3FD5B0-3FA5-4294-ACA7-9AB0763213CF Q48225516-1DA710AD-279A-47C2-8940-D57868337B2D Q48425772-46585C0B-EBD1-4AA1-84B3-72556C06DB57 Q48505037-C1482DCA-C3F9-42D8-B837-A9F40C6BA82A Q50091275-02E79F91-A9EE-4EBB-9DDA-3DB9690BCC92 Q51496414-0C647AAE-9E53-428C-8DA0-7B13AFFAFB10 Q51685125-6C84A8AB-9BD2-4CAE-9595-C34087A9E07F Q54949436-0A54EBC0-013E-44EB-8FD4-05FF81DEB421 Q55043209-EC43CB83-B120-4523-98DE-8D9741DF2E35 Q55104216-461ADD2E-2D8B-43BB-B831-02C22BD08922 Q55424275-9B277220-CA94-4EDE-A2AA-753D866F902B Q55476982-14B834A9-1F30-43A5-93A2-A768524671A2 Q56243541-5389CE00-C199-4D88-AF4D-B6796FEA19DF Q57051319-A3769EA6-861E-48D0-800B-26AA023CD8FD Q58699291-7D5CC199-5E3A-4376-B870-E5F5067A0C2C Q58738843-FC0D4ABF-B19D-4A4D-AAB1-4EE8CC2D6646

P2860

Uremic Toxicity of Advanced Glycation End Products in CKD.

http://www.wikidata.org/entity/Q36514906

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Uremic Toxicity of Advanced Glycation End Products in CKD.

@ast

Uremic Toxicity of Advanced Glycation End Products in CKD.

@en

type

label

Uremic Toxicity of Advanced Glycation End Products in CKD.

@ast

Uremic Toxicity of Advanced Glycation End Products in CKD.

@en

prefLabel

Uremic Toxicity of Advanced Glycation End Products in CKD.

@ast

Uremic Toxicity of Advanced Glycation End Products in CKD.

@en

P1433

Q36514906-08C91D3B-E582-4949-A9BB-1F136F182D41

P1476

Q36514906-35919568-73EF-436A-A269-1A00561A6AE4

P2093

Q36514906-3A31E003-DD91-4E2A-93B5-C7D7E28F2510

Q36514906-6E70DA10-7939-4641-BDD8-B5E7EC7D39F1

Q36514906-770E72B5-5D9E-457A-B7BD-310A30185C95

Q36514906-8AC71E50-2F1A-4BC8-B2A2-D5E3550AA0EF

P2860

Q36514906-00A6BBBC-120C-4AAC-AB0D-B4F64B0010A3

Q36514906-03319FBB-C5DF-4771-B49A-5941C8C8C34B

Q36514906-07852276-8D92-4C5D-B2BE-F0268F18E9E9

Q36514906-09F642FE-3741-4996-A3B8-354CFD7B3B36

Q36514906-0BAECC4C-4EF1-4D89-8E83-6BFF50E7BC63

Q36514906-0CDD2473-C800-403A-A831-36354FD15570

Q36514906-0D08DEA9-8D89-4908-8A9E-8965EEDF2EBC

Q36514906-0D59267B-FCE2-4046-BD98-7A387FF0B6C2

Q36514906-0E18953A-7B07-4DAB-A3A1-9B8B2F1C4552

Q36514906-0E936A70-F63E-45AB-AB0F-F3F185370B9E

P304

Q36514906-6E47703B-62BF-4DE0-83E7-F09A9ED72FDB

P31

Q36514906-DDD2CB8B-43D7-413A-B2B8-E104F74189C8

P356

Q36514906-C6D761EB-17D0-410C-9B3E-FE00C5CEA0D2

P433

Q36514906-9BAAB32E-172D-41E9-9428-6E0A8491F2F7

P478

Q36514906-1A00A29A-47F9-4D06-914A-4EB4A8687FF8

P50

Q36514906-919821F0-9A8A-47DF-8329-FC2440EA35BE

P577

Q36514906-28A14D2D-C12D-4625-A6AE-7D36F6EAD6E7

P698

Q36514906-3D9E74ED-95F2-4E89-8283-9F2DD7EDF642

P932

Q36514906-D03429C5-9675-4DBB-91FD-E25CED89ACE5

P356

P1433

Journal of the American Society of Nephrology

P1476

Uremic Toxicity of Advanced Glycation End Products in CKD.

@en

P2093

Agnès Boullier

http://www.w3.org/2001/XMLSchema#string

Gary E Striker

http://www.w3.org/2001/XMLSchema#string

Helen Vlassara

http://www.w3.org/2001/XMLSchema#string

Ziad A Massy

http://www.w3.org/2001/XMLSchema#string

P2860

Sirt1 modulates premature senescence-like phenotype in human endothelial cells

Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients

Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells

Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis

Does accumulation of advanced glycation end products contribute to the aging phenotype?

Effect of redox modulating NRF2 activators on chronic kidney disease

Role of advanced glycation end products in cellular signaling

Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products

Advanced glycation end products and mortality in hemodialysis patients

Renal catabolism of advanced glycation end products: the fate of pentosidine

P304

354-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2014101047

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26311460

http://www.w3.org/2001/XMLSchema#string

P932

4731113

http://www.w3.org/2001/XMLSchema#string